SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
Clinical Trials of Novel Antiretroviral Therapies
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
12 of
12
|
Single Dose Administration of MK-8527, a Novel nRTTI, in Adults With HIV-1 (ABSTRACT
115)
Russ P. Carstens
Merck & Co., Inc.
Antiviral Activity, Safety, and Pharmacokinetics of GS-1720: A Novel Weekly Oral InSTI (ABSTRACT
116)
Carl J. Fichtenbaum
University of Cincinnati, Cincinnati, OH, USA
VH3810109 (N6LS) in Adults With HIV-1 Who Are ART-Naive-: Phase IIa BANNER Efficacy Data (ABSTRACT
117)
Jan Losos
ViiV Healthcare, Research Triangle Park, NC, USA
A First-in-Human Study of the Trispecific HIV-1 Broadly Neutralizing Antibody, SAR441236 (ABSTRACT
118)
Athe Tsibris
Brigham and Women's Hospital, Boston, MA, USA
QUESTIONS AND ANSWERS (Part 1)
Safety and Efficacy of VRC07-523LS Plus Long-Acting Cabotegravir in the Phase II ACTG A5357 Trial (ABSTRACT
119)
Babafemi Taiwo
Northwestern University, Chicago, IL, USA
Lenacapavir Plus bNAbs for People With HIV and Sensitivity to Either Teropavimab or Zinlirvimab (ABSTRACT
120)
Joseph J. Eron
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Therapeutic Efficacy of a Triple Combination of HIV-1 Broadly Neutralizing Antibodies (ABSTRACT
121)
Boris D. Juelg
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Randomized Trial of Cabotegravir and Rilpivirine Long-Acting in Africa (CARES): Week 48 Results (ABSTRACT
122)
Nicholas Paton
London School of Hygiene & Tropical Medicine, London, UK
QUESTIONS AND ANSWERS (Part 2)
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
12 of
12
|
